In the past two decades, the classical Pap smear has been replaced by liquid-based cytology (LBC), whereas manual reading is now assisted by computer reading. At present, the cytology market is dominated by ThinPrep (Hologic, Bedford, MA, USA) and SurePath/FocalPoint (BD, Franklin Lakes, NJ, USA) technologies. The advantages of LBC include purified stains, cell monolayers, and the ability to run additional analyses on the same sample, for example, for human papillomavirus (HPV) or biomarker expression testing. Computer-assisted reading systems deselect normal samples and point cytologists to the most critical areas in suspect samples.

The use of the new technologies has also affected women. In two routine Danish laboratories, the switch to SurePath LBC significantly increased the proportions of abnormal cytological samples at age \<45 years, and decreased them in older women ([@bib4]; [@bib14]). ThinPrep LBC in another Danish laboratory was associated with a decreased proportion of abnormal cytological samples at any age. This decrease was especially large around menopause, possibly because LBC makes neoplastic lesions more easily distinguished from, for example, atrophy. Computer-assisted reading technologies increased the proportions of abnormal cytology regardless of the brand and the woman\'s age.

These changes led to a different selection of women referred for further follow-up. The next question is, therefore, whether there was also a change in the detection of high-grade cervical intraepithelial neoplasia (CIN). Previous trials comparing LBC and/or computer-assisted reading to conventional methods led to conflicting results regarding the changed CIN detection; some suggested a statistically significantly decreased, some equal, and some a significantly increased detection ([@bib1]; [@bib11]; [@bib12]).

Based on routine screening data from four laboratories evaluating about one-third of all cytology in Denmark, we aimed to determine whether the age-specific changes in abnormal cytology described above led to changes in the detection of histologically confirmed high-grade CIN.

Materials and methods
=====================

Cervical screening has been undertaken in Denmark since the 1960s. In 1986, organised cytological screening at age 23--59 years was recommended every 3 years. Since 2007, women aged 50--65 years have been targeted every 5 years, whereas since 2012, women aged ⩾60 years can be 'checked out\' of the programme following a negative HPV test result. Screening coverage has been around 75%, with negligible regional variation.

Previously, we studied changes in the detection of atypical squamous cells of undetermined significance or worse (⩾ASCUS) following the introduction of LBC and computer-assisted reading technologies in 1998--2007 in Departments of Pathology of Copenhagen University Hospital Hvidovre, Hillerød Hospital, and Odense University Hospital ([Table 1](#tbl1){ref-type="table"}) ([@bib3]; [@bib14]). Department of Pathology of Roskilde County Hospital, retaining manually read conventional cytology, was used to study technology-independent changes, for example, changes in the background risk of cervical cancer. Each laboratory served well-defined catchment areas: Hvidovre laboratory received samples from Copenhagen and Frederiksberg Municipalities; Hillerød from Frederiksborg County; Roskilde from Roskilde County; and Odense from Funen County. The coverage rates of the target population were stable, as was the case-mix of samples (screening *vs* follow-up).

Data sources
------------

We retrieved the information on the women\'s age and place of residence from the Danish Civil Registration System. Since 1968, every resident has been registered with a unique identification number (CPR number). Data on cervical cytology and biopsies including their diagnoses were obtained from the Pathology Data Bank (Patobank). We also retrieved data on conisations from the Patobank; since mid-1990s, conisations were most frequently undertaken as large loop excisions of the transformation zone and had a specific Danish Systematised Nomenclature of Medicine (SNOMED) code. Additional data on cervical treatments including conisations, destructive therapies, hysterectomies, excisions, and other less frequent types of treatment ([@bib2]) were retrieved from (a) the National Patient Register where information on in-patient treatments and the associated diagnoses has been available since 1978, and on out-patient treatments since 1995, and from (b) the National Health Service Register containing non-diagnostic information on biopsies and cervical treatments undertaken by private gynaecologists since 1990. The Danish Cancer Register was used to obtain information on incident cervical cancers since 1943. Data were retrieved from the beginning of the registration until end of 2010 and were linked using the CPR number.

In the Patobank, diagnoses were registered using the SNOMED classification. Diagnoses were classified into Bethesda 2001 categories. An exception was made for Hvidovre ([@bib4]), where samples from women aged ⩾30 years with an initial ASCUS diagnosis and a negative reflex HPV test were, during a limited time period, routinely downgraded to normal cytology. As these women were recommended for repeated testing despite the nominally normal diagnosis, we reclassified them as having ASCUS.

Technology phases
-----------------

Laboratories were autonomous in making decisions regarding the technology and the combinations of slide preparation and reading technologies differed even between the laboratories that used the same brand. Consequently, data were analysed for each laboratory separately.

As described previously ([@bib3]; [@bib14]), technological phases were identified by slide preparation, reading technique, and triage of ASCUS at ⩾30 years. All piloting and implementation periods were excluded. 'Baseline\' in phase 1 was defined for all laboratories as manual reading of conventional cytology with cytological triage of ASCUS. The Odense laboratory returned to manually read conventional cytology after a ThinPrep LBC pilot. Because the differences in the proportions of all studied end points were not statistically significant, data for pre- and postpilot periods were merged (excluding the pilot).

In phase 2, Hvidovre laboratory started using FocalPoint reading technology. FocalPoint Slide Profiler replaced manual reading, and the cutoff for no further review of normal samples was set to 50% following an internal pilot. The remaining samples were automatically divided into five quintiles of likelihood of abnormalities. In phase 3, SurePath LBC replaced conventional cytology, whereas the laboratory continued using FocalPoint Slide Profiler with a 50% cutoff. This cutoff was changed to the manufacturer\'s recommended 25% in phase 4, meaning that cytotechnicians and pathologists had to evaluate 75% instead of 50% of all samples. Additionally, cytology was replaced by HPV testing in triage of ASCUS at age ⩾30 years using Qiagen\'s Hybrid Capture 2 (HC2) assay. In phase 5, FocalPoint GS Imaging System was added, which, in the 75% of samples not automatically signed out by the FocalPoint Slide Profiler, guided the cytotechnicians through 16 preselected fields of view (most likely to contain abnormalities).

Hillerød laboratory closely followed the changes made in Hvidovre. In phase 2, it introduced FocalPoint Slide Profiler with the 50% cutoff, which was changed to 25% in phase 3 together with introducing SurePath LBC. In phase 4, FocalPoint GS Imaging System was added. Throughout the study period, ASCUS was triaged with cytology.

Odense laboratory started using ThinPrep technology in phase 2 when conventional cytology was replaced by LBC using ThinPrep Pap test in T3000 processor (Hologic). In phase 3, ThinPrep Imaging System (Hologic) including Imaging Pap Stain replaced conventional Pap stain and manual reading. The system guided the cytotechnician to 22 fields of view. Also here, cytology was used to triage ASCUS in all phases.

To determine potential trends in Roskilde, manually read conventional cytology data were analysed in arbitrary 3-year periods.

Inclusion criteria
------------------

We included samples taken from 1 January 1998 to 31 December 2007 at age 23--59 years, the target age until 2007. As an exception, we excluded year 2007 for Hillerød and Roskilde since a national administrative reorganisation led to changes in their catchment areas. Samples taken for follow-up of recent abnormalities were excluded. Previous analyses ([@bib3]; [@bib14]) used the same definitions.

The worst histological outcome was determined within 2.5 years after the abnormal cytological sample. Women who died or emigrated from Denmark during the follow-up were excluded. Some biopsies were evaluated by private pathologists who were historically not obliged to report their diagnostic data to the Patobank. Women were, therefore, also excluded if they lived in, or moved to, a county with inadequate histological registration in the Patobank, defined as registration of \<85% of all biopsies ([@bib2]). This implies exclusion of samples from Hillerød before 1 January 2003, and from Hvidovre/Frederiksberg before 1 January 2001.

Samples taken for follow-up of recent abnormalities were those with a preceding cervical cancer diagnosis; CIN diagnosis or treatment in ⩽10 years; high-grade cervical squamous intraepithelial lesions or worse (⩾HSIL), inadequate cytology, or a positive HPV test result in the past 12 months; and inadequate/negative histology, low-grade cervical intraepithelial lesions, or ASCUS in the past 15 months. The remaining were predominantly screening samples, taken either in organised or opportunistic settings. As the indication for sample taking was not registered, they may have also contained a small proportion of samples taken for investigation of symptoms. The proportion of the latter samples was assumed not to be associated with the technological phases.

Statistical analysis
--------------------

ASCUS was the cutoff for abnormal cytology as it was the indication for further follow-up. The following end points were determined per 100 screening samples: detection of histologically confirmed CIN2 and ⩾CIN3, number of CIN treatments (all indicators of cytology\'s sensitivity), detection of histologically confirmed \<CIN2, and number of false-positive samples (indicators of specificity). False-positive samples were defined as ⩾ASCUS without ⩾CIN2 or ⩾CIN3 during follow-up ([@bib16]). Cervical intraepithelial neoplasia treatments included all conisations (most frequently undertaken as large-loop excision of the transformation zone), and destructive therapies, hysterectomies, excisions, and other less frequent treatments if histological CIN of any grade was registered in the period between 3 months before and 1 month after the treatment ([@bib2]). We calculated the positive predictive value (PPV) for ⩾CIN2 and ⩾CIN3 as the number of detected lesions per 100 screening samples with an ⩾ASCUS diagnosis.

The main comparison was between manually read conventional cytology (baseline/phase 1) and full implementation of modern cytological technologies by end of 2007 (the last phase per laboratory). Per laboratory, we calculated relative proportions (RPs) of the observed end points in the final phase compared with the baseline. The data for the baseline situation were not available for Hvidovre/Frederiksberg and Hillerød, thus these laboratories did not contribute here. To assess the contribution of each change in technology, we also calculated RP comparing with the previous phase. We stratified the comparisons by age group (23--29, 30--44, and 45--59 years). The 95% confidence intervals (CI) for RP were calculated assuming log-normal distribution.

Proportions of ⩾ASCUS were a focus of previous publications ([@bib4]; [@bib14]), and were not further discussed here. Because for the present analysis the definition of the at-risk population excluded women whose histological outcomes could not be reliably determined, these proportions were tabulated anew. The proportions of women with ⩾ASCUS with and without the exclusion were similar.

Results
=======

Study population
----------------

In total, 674 248 samples were included: 151 135 from Roskilde, 283 310 from Hvidovre/Copenhagen, 38 831 from Hvidovre/Frederiksberg, 71 915 from Hillerød, and 129 057 from Odense ([Table 2](#tbl2){ref-type="table"}). Relatively few samples from counties with incomplete histological registration were excluded ([Table A1](#tblA1){ref-type="table"}), most often from Hvidovre serving the area with traditionally highest rates of migration to other counties. The age distribution and completeness of routine follow-up did not change substantially between phases in each laboratory. Most abnormal samples (⩾90%) had follow-up. The Roskilde, Odense, and Hillerød laboratories served a population with a higher average age than Hvidovre ([Table A2](#tblA2){ref-type="table"}).

Changes in the laboratory with continuous use of manually read conventional cytology
------------------------------------------------------------------------------------

In Roskilde, few changes between the last and the first phase were observed ([Table 3](#tbl3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}: detection of ⩾CIN2; [Figure 2](#fig2){ref-type="fig"}: detection of \<CIN2; and [Figure 3](#fig3){ref-type="fig"}: false-positive tests). The changes were only significant for the proportions of false-positive tests and \<CIN2 biopsies, particularly at 45--59 years. A more detailed phase-by-phase comparison by age revealed some fluctuations but no trends ([Table A3](#tblA3){ref-type="table"}).

Changes with SurePath technologies
----------------------------------

In Hvidovre/Copenhagen, full implementation of SurePath/FocalPoint LBC and reading technologies compared with manually read conventional cytology was associated with a doubling of the frequency of all studied outcomes at 23--44 years, with the exception of a decreased PPV for ⩾CIN2/⩾CIN3. In older women, 45--59 years, the only statistically significant change was a doubling of the frequency of false-positive tests, and a corresponding decrease in the PPV.

The first step toward computer-assisted reading using a 50% cutoff on FocalPoint Slide Profiler (comparing phase 2 with phase 1, using conventional cytology and cytological triage of ASCUS in both phases) had little impact on the studied outcomes ([Table A4](#tblA4){ref-type="table"}). At 23--29 years, however, the frequency of \<CIN2 biopsies and false-positive tests increased significantly by 10--30%. At 45--59 years, detection of ⩾CIN3 statistically significantly decreased (by 36%). The overall PPV for ⩾CIN2/⩾CIN3 decreased by 13%.

SurePath LBC implementation (comparing phase 3 with phase 2, using FocalPoint Slide Profiler for reading with a 50% cutoff and cytological triage of ASCUS in both phases) was associated with a statistically significantly increased detection of \<CIN2, high-grade CIN, and the frequency of CIN treatments at 23--29 years, all by 30--40%, and in the frequency of false-positive tests by \>50%. The increases were slightly smaller at 30--44 years. In women around menopause, 45--59 years, the decreases in CIN detection and in false-positive tests after the introduction of LBC were generally not statistically significant.

After a change in the FocalPoint Slide Profiler\'s cutoff from 50 to 25%, and a concurrent introduction of HPV triage for ASCUS (comparing phase 4 to phase 3 using SurePath LBC in both phases), statistically significant increases in all studied outcomes were observed at 23--44 years (by ∼+20--30%). At 45--59 years, significantly increased frequency was observed for \<CIN2 biopsies (+23%), ⩾CIN3 (+66%), and false-positive tests (+73%).

The addition of FocalPoint GS Imaging System (comparing phase 5 with phase 4, using FocalPoint Slide Profiler with a 25% cutoff, SurePath LBC, and HC2 triage of ASCUS in both phases) was associated with statistically insignificant increases in the frequency of most studied outcomes. However, at 30--59 years, the frequency of false-positive tests increased significantly (by ∼+20%), and so did the frequency of \<CIN2 biopsies at 23--44 years (+25--30%).

Similar patterns in the RP of the studied outcomes across phases were seen also at Hvidovre/Frederiksberg ([Table A5](#tblA5){ref-type="table"}) and Hillerød ([Table A6](#tblA6){ref-type="table"}).

Changes with ThinPrep technologies
----------------------------------

After full implementation of ThinPrep LBC and reading technologies in Odense, the detection of CIN2 and the frequency of CIN treatments statistically significantly increased at 23--29 years, by 77 and 22%, respectively. Among older women, the decreases in the frequency of \<CIN2 biopsies (−29% at 30--44 years and −61% at 45--59 years) and of false-positive tests (−36% at 30--44 years and −65% at 45--59 years) were statistically significant ([Table 3](#tbl3){ref-type="table"}). Correspondingly, the overall PPV increased by 51% (for ⩾CIN2) and 41% (for ⩾CIN3); at age 45--59 years, the increase was particularly high, 105% for ⩾CIN2.

ThinPrep LBC implementation (comparing phase 2 with phase 1, using manual reading in both phases) was associated with a statistically significant decrease in the frequency of false-positive tests at all ages (−18% at 23--29 years, −53% at 30--44 years, and −76% at 45--59 years; [Table A7](#tblA7){ref-type="table"}). The frequency of \<CIN2 biopsies also decreased (−41% at 30--44 years and −69% at 45--59 years). There was a tendency toward a decreased detection of CIN2 and a slightly increased detection of ⩾CIN3 in all three age groups, although these changes were not statistically significant. The PPV increased particularly at 30--44 years (by 83% for ⩾CIN3) and at 45--59 years (by 302% for ⩾CIN3).

With ThinPrep Imaging System (comparing phase 3 with phase 2, using ThinPrep LBC in both phases), the detection of CIN2 at 23--29 years increased significantly (+135%), and detection of ⩾CIN3 at 45--59 years decreased (−53%). Also, the frequency of false-positive tests increased, by 34% at 30--44 years, and by 45% at 45--59 years. Consequently, the PPV decreased, by 24% (for ⩾CIN3) at 23--29 years, and by 63% (for ⩾CIN3) at 45--59 years.

Discussion
==========

General findings
----------------

In the Danish routine screening data, cytology using SurePath LBC and FocalPoint computer-assisted reading technologies (with possibly also an intervening effect of HPV triage) appeared to be more sensitive for the detection of high-grade CIN but less specific compared with manually read conventional cytology, predominantly at younger ages. ThinPrep LBC, on the other hand, decreased the sensitivity toward CIN2, but with higher specificity compared with conventional cytology, particularly at older ages. ThinPrep computer-assisted reading technologies were associated with a decrease in the specificity compared with manual reading, but generally without corresponding increases in high-grade CIN detection other than of CIN2 in young women.

Comparison with the literature
------------------------------

In particular, the early literature on new cytological technologies was dominated by studies in the so-called 'referral populations\'. These women represented selected subgroups of the screening population ([@bib18]), identified as eligible after presenting with abnormal conventional cytology. Hence, unlike in our study, lesions detectable using LBC but less likely to be seen on conventional cytology would not be considered. This might be one of the reasons why an influential meta-analysis from 2008 concluded that LBC is as sensitive for detection of ⩾CIN2 as conventional cytology, relative sensitivity 1.03 (95% CI: 0.97--1.09) ([@bib1]).

The LBC literature on primary screening has been dominated by ThinPrep studies, but those led to widely differing results. In a small French screening study (*n*=1757), in which all women underwent colposcopy, the sensitivity of ThinPrep LBC was 66% (95% CI: 56--75), slightly but significantly (*P*\<0.05) lower compared with that of conventional cytology, 72% (95% CI: 63--80) ([@bib6]). In that study, LBC slides were made from the material remaining after the conventional slides had been prepared. Consistent with our data, two large randomised controlled trials, from the Netherlands (*n*=89 784) and Italy (*n*=45 174), observed the same detection of high-grade CIN with ThinPrep LBC and conventional cytology ([@bib19]; [@bib21]). However, in a smaller Swedish trial (*n*=13 484) ThinPrep LBC detected 62% (95% CI: 22--116) more high-grade CIN compared with conventional cytology ([@bib23]). Also in a German trial comparing ThinPrep LBC with conventional cytology at ⩾20 years (*n*=20 935) ([@bib12]), ThinPrep LBC detected substantially more ⩾CIN2 compared with conventional cytology, RR: 2.40 (95% CI: 1.49--3.87). Although other factors probably also had a role, the sensitivity of conventional cytology might have differed across these studies. Reading of conventional cytology tended to rely on internal training, potentially allowing for interlaboratory variation. For patented LBC technologies, the training and certification is the manufacturer\'s responsibility, and the clinical outcomes thereof might be more uniform across laboratories.

A dearth of SurePath LBC studies with histological confirmation of CIN created a void in the literature, thus our findings of an increased sensitivity at younger ages could not be adequately compared. There are three major differences between ThinPrep and SurePath LBC that may have contributed to the observed variation in CIN detection. First, ThinPrep contains methanol, whereas SurePath contains formaldehyde and ethanol, leading to a different morphology presentation on the final microscopy slide. Second, SurePath cell material is first cleaned up for mucus and debris on a column. ThinPrep is processed directly out of the vial; samples are aspirated through a filter and dispensed onto the slide, which potentially leaves cell material in the filter. Finally, for a ThinPrep sample, the brush is rinsed in the liquid and afterwards discarded by the smear taker, whereas the brush head is left in SurePath until the cell material is transferred to the preprocessing column before sedimentation on the cytology slide in the laboratory. Taken together with the different vial sizes (20 ml for ThinPrep and 10 ml for SurePath), this may potentially yield differences in the available cellularity ([@bib5]; [@bib24]).

There have been few large evaluations of computer-assisted reading technology with a histological reference. Most notably, the large UK randomised controlled trial MAVARIC (*n*=73 266) compared ThinPrep and FocalPoint imaging-assisted reading with manual reading in predominantly primary screening samples ([@bib10]). Samples from some non-randomised practices and from colposcopy clinics were included to raise the number of abnormal samples. Unlike in our study, both ThinPrep and FocalPoint were inferior in detecting high-grade CIN; compared with manual reading, the relative sensitivity for ⩾CIN2 was 0.92 (95% CI: 0.87--0.98) for ThinPrep and 0.90 (95% CI: 0.85--0.96) for FocalPoint. In the German trial, the addition of computer-assisted reading to LBC slightly increased the relative detection of ⩾CIN2 compared with manually read conventional cytology, from 2.40 (with ThinPrep LBC alone, see above) to 2.70 (95% CI: 1.69--4.31; for ThinPrep LBC+computer-assisted reading). Also in two large Australian screening laboratories, ThinPrep LBC combined with Imaging missed fewer high-grade CIN compared with manually read conventional cytology ([@bib7]; [@bib8]).

Strengths and weaknesses
------------------------

We included routine samples from women targeted by the Danish screening programme. Abnormalities were verified through four nation-wide registers. Abnormal cytology was defined as any abnormality that would trigger follow-up, either through repeated testing or a referral for colposcopy. Histology was ascertained practically throughout the whole three-yearly screening round, and only periods with highly complete histological registration were included. Compared with other studies of routine screening, the proportion of women with histological verification of ⩾ASCUS was relatively high. We excluded all piloting and implementation periods. Although some remaining learning curve effects cannot be entirely dismissed ([@bib9]), the outcomes of our study should be representative for a 'normal\' use of the evaluated technologies.

As a limitation, it should be emphasised that ThinPrep data were based on a single laboratory. This laboratory started with a high proportion of cytological abnormalities ([@bib14]), possibly signifying a relatively high sensitivity and low specificity for detecting high-grade CIN to begin with. In this laboratory, a clear advantage of ThinPrep technologies was an improvement in screening specificity.

Inferences regarding causation should be made cautiously. A competing explanation for the observed changes could be a changed risk of cervical lesions. This is, however, unlikely. First, the changes in the laboratory that continuously used manually read conventional cytology were of a substantially smaller magnitude compared with in the laboratories with changing technologies. Second, the laboratories served catchment areas in relatively close geographical proximity, and no change during the study period with a potentially differential effect on the background risk of cervical cancer could be identified.

Our study covered a 10-year period plus 2.5-year follow-up, during which the women\'s sociodemographic characteristics and screening histories may have changed. Ideally, these would have been adjusted for in the analysis. The age structure changed very little, and all analyses were age-stratified. Given Denmark\'s homogeneity, any changes in the sociodemographic factors would affect Roskilde\'s catchment area in a similar way as those of other laboratories.

In our analysis, we focused on relative changes. The catchment area of Hvidovre to a higher extent included an urban population, thus absolute age-specific levels of disease detection may not have been comparable across the four laboratories. Hence, technologies were compared strictly within individual laboratories.

Clinical implications
---------------------

The combination of screening and triage tests should offer the highest sensitivity for high-grade CIN and an acceptable PPV of an immediate referral to colposcopy. For reasons of cost, logistics, and women\'s discomfort, it is preferable to perform all screening and triage tests on the same sample. A consideration of an optimal medium for sample storage is, therefore, going to have a role also when the switch is going to be made from the present cytology-based screening with HPV triage to the imminent HPV-based screening with cytology triage. Critics have claimed that SurePath LBC medium might be unsuitable for HPV testing ([@bib13]), and none of the US Food and Drug Administration approvals for HPV assays were granted for samples stored in SurePath. Only few HPV studies evaluated SurePath samples, in particular the Danish Horizon study evaluating APTIMA, cobas, HC2, and CLART assays ([@bib17], [@bib18], [@bib15]). The challenge with SurePath in HPV testing is its formaldehyde content, which induces covalent bindings between protein structures and the HPV\'s genetic material. These render the genetic material inaccessible to enzyme-driven amplification or detection. However, a preheating step reverses the bindings ([@bib22]). As a result, invalid HPV test results that would suggest inaccessible genetic material tend to be infrequent ([@bib18]). Against this background, the improved detection of high-grade CIN in SurePath samples observed in our study might be relevant also for HPV-based screening with cytology triage.

When changes are made to screening programmes, it is worth keeping in mind the more general finding from this study, in that replacing or adjusting a screening test can cause a shift in the population who tests positive, is referred for further follow-up, and finally treated. More sensitive screening methods may shift the detection toward smaller CIN lesions with a lower potential for progression ([@bib20]). In our study, an increased detection with LBC and/or computer-assisted reading with either brand was observed particularly at relatively young ages, when lesions less likely progress ([@bib25]). To optimise screening recommendations with respect to the technology, future analyses of interval cervical cancers should determine to what extent the observed increases in the sensitivity of cytology represented overtreatment or a reduction in the burden of cervical cancer.

In conclusion, this study confirmed our earlier findings that modern cytological technologies have not been neutral with respect to the detection of cervical disease. In the Danish setting, the trends in the sensitivity and specificity depended on the type and the brand of the technology, and the age of the screened women. In essence, SurePath-based technology increased the sensitivity of cytology for high-grade cervical lesions predominantly at younger ages, whereas ThinPrep-based technology increased the specificity predominantly at older ages.
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![**Frequency of histologically confirmed ⩾CIN2, by laboratory and phase.** Roskilde: manually read conventional cytology in all phases. Hvidovre and Hillerød: SurePath/FocalPoint reading and liquid-based cytology technologies. Odense: ThinPrep reading and liquid-based cytology technologies. ○, 23--29 years; □, 30--44 years; ◊, 45--59 years. Phases as described in [Table 1](#tbl1){ref-type="table"}. CPH M, Copenhagen Municipality.](bjc2015339f1){#fig1}

![**Frequency of histologically confirmed \<CIN2, by laboratory and phase.** Roskilde: manually read conventional cytology in all phases. Hvidovre and Hillerød: SurePath/FocalPoint reading and liquid-based cytology technologies. Odense: ThinPrep reading and liquid-based cytology technologies. ○, 23--29 years; □, 30--44 years, and ◊, 45--59 years. Phases as described in [Table 1](#tbl1){ref-type="table"}. CPH M, Copenhagen Municipality.](bjc2015339f2){#fig2}

![**Frequency of false-positive tests for ⩾CIN2 (samples with abnormal cytology that were not followed by a histological diagnosis of ⩾CIN2), by laboratory and phase.** Roskilde: manually read conventional cytology in all phases. Hvidovre and Hillerød: SurePath/FocalPoint reading and liquid-based cytology technologies. Odense: ThinPrep reading and liquid-based cytology technologies. ○, 23--29 years; □, 30--44 years; ◊, 45--59 years. Phases as described in [Table 1](#tbl1){ref-type="table"}. CPH M, Copenhagen Municipality.](bjc2015339f3){#fig3}

###### Description of phases by laboratory

  Laboratory (county catchment area) and phase                                            Period                                 Slide preparation                                          Reading technique                                                   Triage
  --------------------------------------------------------------------------------------- -------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------
  **Roskilde (Roskilde County)**                                                                                                                                                                                                                                
  Phase 1                                                                                 1 January 1998 to 31 December 2000     Conventional cytology                                      Manual                                                              Cytology
  Phase 2                                                                                 1 January 2001 to 31 December 2003     As above                                                   As above                                                            As above
  Phase 3                                                                                 1 January 2004 to 31 December 2006     As above                                                   As above                                                            As above
  **Hvidovre (Copenhagen and Frederiksberg Municipalities)[a](#t1-fn3){ref-type="fn"}**                                                                                                                                                                         
  Phase 1                                                                                 1 January 1998 to 30 September 1999    Conventional cytology                                      Manual                                                              Cytology
  Phase 2                                                                                 1 July 2000 to 30 April 2002           As above                                                   Computer-assisted (BD FocalPoint Slide Profiler, 50% cutoff)        As above
  Phase 3                                                                                 1 August 2002 to 30 April 2005         LBC (SurePath Pap test, BD PrepStain Slide Processor)      As above                                                            As above
  Phase 4                                                                                 1 October 2005 to 30 November 2006     As above                                                   Computer-assisted (BD FocalPoint Slide Profiler, 25% cutoff)        HPV DNA (Qiagen Hybrid Capture 2)[b](#t1-fn4){ref-type="fn"}
  Phase 5                                                                                 1 April 2007 to 31 December 2007       As above                                                   Computer-assisted (as above plus BD FocalPoint GS Imaging System)   As above
  **Hillerød (Frederiksborg County)[c](#t1-fn5){ref-type="fn"}**                                                                                                                                                                                                
  Phase 1                                                                                 1 January 1998 to 31 July 2002         Conventional cytology                                      Manual                                                              Cytology
  Phase 2                                                                                 1 September 2002 to 31 December 2003   As above                                                   Computer-assisted (BD FocalPoint Slide Profiler, 50% cutoff)        As above
  Phase 3                                                                                 1 October 2004 to 31 October 2005      LBC (BD SurePath Pap test, BD PrepStain Slide processor)   Computer-assisted (BD FocalPoint Slide Profiler, 25% cutoff)        As above
  Phase 4                                                                                 1 February 2006 to 31 October 2006     As above                                                   Computer-assisted (as above plus BD FocalPoint GS Imaging System)   As above
  **Odense (Funen County)**                                                                                                                                                                                                                                     
  Phase 1a                                                                                1 January 1998 to 31 December 1998     Conventional cytology                                      Manual                                                              Cytology
  Phase 1b                                                                                1 November 1999 to 31 May 2001         As above                                                   As above                                                            As above
  Phase 2                                                                                 1 January 2004 to 30 September 2004    LBC (Hologic ThinPrep Pap test, T3000 Slide Processor)     As above                                                            As above
  Phase 3                                                                                 1 October 2006 to 31 December 2007     As above                                                   Computer-assisted (Hologic ThinPrep Imaging System)                 As above

Abbreviations: ASCUS=atypical squamous cells of undetermined significance; HPV=human papillomavirus; LBC=liquid-based cytology.

*Note*: All periods between phases represented periods of piloting and implementation of the technology, and were excluded from the study.

Owing to incomplete histological registration before 2001 for women residing in Frederiksberg Municipality, data were analysed separately by municipality (from phase 1 onwards for women residing in Copenhagen Municipality, and for Frederiksberg Municipality only from phase 2 onwards).

This also signifies a change in the recommended follow-up. Whereas with cytological triage, all women with ASCUS were recommended for repeated testing at 6/12 months, they were recommended for immediate colposcopy if HPV-positive, and for repeated testing in 12 months if HPV-negative.

Owing to incomplete histological registration for women residing in Frederiksborg County, only data for samples taken from 1 January 2003 onwards were included in the analysis, that is, from phase 2 onwards.

###### Primary cytology samples and histological outcomes after 2.5-year follow-up[a](#t2-fn3){ref-type="fn"}

                                                                                              Phase 1                                                                                        Phase 2                                                                                          Phase 3                                                                                                  Phase 4                                                                                                            Phase 5
  --------------------------------------------------- ---------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  **Unchanged technology: Roskilde**                   Baseline: Conventional cytology, manual reading, cytology triage of ASCUS (*N*=53 979)              Conventional cytology, manual reading, cytology triage of ASCUS (*N*=49 856)                    Conventional cytology, manual reading, cytology triage of ASCUS (*N*=47 300)                                                             Not relevant                                                                                                        Not relevant
  ⩾ASCUS                                                                                     1173 (2%)                                                                                    **1251 (3%)**                                                                                    **1012 (2%)**                                                                                                 ---                                                                                                                ---
  CIN2                                                                                      118 (0.22%)                                                                                    104 (0.21%)                                                                                      85 (0.18%)                                                                                                   ---                                                                                                                ---
  ⩾CIN3                                                                                     281 (0.52%)                                                                                    289 (0.58%)                                                                                      271 (0.57%)                                                                                                  ---                                                                                                                ---
  CIN treatments                                                                             482 (0.9%)                                                                                     491 (1.0%)                                                                                    **405 (0.9%)**                                                                                                 ---                                                                                                                ---
  \<CIN2                                                                                    471 (0.87%)                                                                                    439 (0.88%)                                                                                    **323 (0.68%)**                                                                                                ---                                                                                                                ---
  False positive for ⩾CIN2                                                                   774 (1.4%)                                                                                   **858 (1.7%)**                                                                                  **656 (1.4%)**                                                                                                 ---                                                                                                                ---
  False positive for ⩾CIN3                                                                   892 (1.7%)                                                                                   **962 (1.9%)**                                                                                  **741 (1.6%)**                                                                                                 ---                                                                                                                ---
  PPV for ⩾CIN2                                                                                 34%                                                                                            31%                                                                                              35%                                                                                                      ---                                                                                                                ---
  PPV for ⩾CIN3                                                                                 24%                                                                                            23%                                                                                            **27%**                                                                                                    ---                                                                                                                ---
  **SurePath technology: Hvidovre (Copenhagen)**       Baseline: Conventional cytology, manual reading, cytology triage of ASCUS (*N*=62 644)   Conventional cytology, FocalPoint Slide Profiler 50% cutoff, cytology triage of ASCUS (*N*=59 274)   SurePath LBC, FocalPoint Slide Profiler 50% cutoff, cytology triage of ASCUS (*N*=94 541)                  SurePath LBC, FocalPoint Slide Profiler 25% cutoff, HC2 triage of ASCUS (*N*=43 002)                   SurePath LBC, FocalPoint Slide Profiler 25% cutoff+FocalPoint Imaging System, HC2 triage of ASCUS (*N*=23 849)
  ⩾ASCUS                                                                                     2299 (4%)                                                                                      2307 (4%)                                                                                      **4832 (5%)**                                                                                            **2751 (6%)**                                                                                                      **1742 (7%)**
  CIN2                                                                                      230 (0.37%)                                                                                    201 (0.34%)                                                                                    **423 (0.45%)**                                                                                          **242 (0.56%)**                                                                                                      162 (0.68%)
  ⩾CIN3                                                                                     624 (1.00%)                                                                                    547 (0.92%)                                                                                   **1148 (1.21%)**                                                                                          **641 (1.49%)**                                                                                                      394 (1.65%)
  CIN treatments                                                                             857 (1.4%)                                                                                     828 (1.4%)                                                                                    **1780 (1.9%)**                                                                                          **959 (2.2%)**                                                                                                      **603 (2.5%)**
  \<CIN2                                                                                    722 (1.15%)                                                                                  **801 (1.35%)**                                                                                 **1414 (1.50%)**                                                                                          **844 (1.96%)**                                                                                                    **581 (2.44%)**
  False positive for ⩾CIN2                                                                  1445 (2.3%)                                                                                  **1559 (2.6%)**                                                                                  **3261 (3.4%)**                                                                                          **1868 (4.3%)**                                                                                                    **1186 (5.0%)**
  False positive for ⩾CIN3                                                                  1675 (2.7%)                                                                                  **1760 (3.0%)**                                                                                  **3684 (3.9%)**                                                                                          **2110 (4.9%)**                                                                                                    **1348 (5.7%)**
  PPV for ⩾CIN2                                                                                 37%                                                                                          **32%**                                                                                            33%                                                                                                      32%                                                                                                                32%
  PPV for ⩾CIN3                                                                                 27%                                                                                          **24%**                                                                                            24%                                                                                                      23%                                                                                                                23%
  **SurePath technology: Hvidovre (Frederiksberg)**                                Baseline: As above (excluded)                                                                       As above (*N*=9385)                                                                             As above (*N*=17 634)                                                                                     As above (*N*=7018)                                                                                                As above (*N*=4794)
  ⩾ASCUS                                                                                        ---                                                                                          361 (4%)                                                                                      **830 (5%)**                                                                                             **420 (6%)**                                                                                                        **352 (7%)**
  CIN2                                                                                          ---                                                                                         26 (0.28%)                                                                                    **77 (0.44%)**                                                                                           **51 (0.73%)**                                                                                                        39 (0.81%)
  ⩾CIN3                                                                                         ---                                                                                         97 (1.03%)                                                                                      195 (1.11%)                                                                                            **107 (1.52%)**                                                                                                       80 (1.67%)
  CIN treatments                                                                                ---                                                                                         134 (1.4%)                                                                                      304 (1.7%)                                                                                             **169 (2.4%)**                                                                                                        140 (2.9%)
  \<CIN2                                                                                        ---                                                                                        113 (1.20%)                                                                                      239 (1.36%)                                                                                              105 (1.50%)                                                                                                      **122 (2.54%)**
  False positive for ⩾CIN2                                                                      ---                                                                                         238 (2.5%)                                                                                    **558 (3.2%)**                                                                                           **262 (3.7%)**                                                                                                      **233 (4.9%)**
  False positive for ⩾CIN3                                                                      ---                                                                                         264 (2.8%)                                                                                    **635 (3.6%)**                                                                                           **313 (4.5%)**                                                                                                      **272 (5.7%)**
  PPV for ⩾CIN2                                                                                 ---                                                                                            34%                                                                                              33%                                                                                                      38%                                                                                                                34%
  PPV for ⩾CIN3                                                                                 ---                                                                                            27%                                                                                              23%                                                                                                      25%                                                                                                                23%
  **SurePath technology: Hillerød**                     Baseline: Conventional cytology, manual reading, cytology triage of ASCUS (excluded)    Conventional cytology, FocalPoint Slide Profiler 50% cutoff, cytology triage of ASCUS (*N*=28 888)   SurePath LBC, FocalPoint Slide Profiler 25% cutoff, cytology triage of ASCUS (*N*=24 593)   SurePath LBC, FocalPoint Slide Profiler 25% cutoff+FocalPoint Imaging System, cytology triage of ASCUS (*N*=18 434)                                                    Not relevant
  ⩾ASCUS                                                                                        ---                                                                                          878 (3%)                                                                                      **865 (4%)**                                                                                             **843 (5%)**                                                                                                            ---
  CIN2                                                                                          ---                                                                                         67 (0.23%)                                                                                      71 (0.29%)                                                                                             **77 (0.42%)**                                                                                                           ---
  ⩾CIN3                                                                                         ---                                                                                        151 (0.52%)                                                                                    **183 (0.74%)**                                                                                          **181 (0.98%)**                                                                                                          ---
  CIN treatments                                                                                ---                                                                                         281 (1.0%)                                                                                    **291 (1.2%)**                                                                                           **280 (1.5%)**                                                                                                           ---
  \<CIN2                                                                                        ---                                                                                        318 (1.10%)                                                                                      298 (1.21%)                                                                                            **275 (1.49%)**                                                                                                          ---
  False positive for ⩾CIN2                                                                      ---                                                                                         660 (2.3%)                                                                                      611 (2.5%)                                                                                             **585 (3.2%)**                                                                                                           ---
  False positive for ⩾CIN3                                                                      ---                                                                                         727 (2.5%)                                                                                      682 (2.8%)                                                                                             **662 (3.6%)**                                                                                                           ---
  PPV for ⩾CIN2                                                                                 ---                                                                                            25%                                                                                            **29%**                                                                                                    31%                                                                                                                ---
  PPV for ⩾CIN3                                                                                 ---                                                                                            17%                                                                                            **21%**                                                                                                    21%                                                                                                                ---
  **ThinPrep technologies: Odense**                    Baseline: Conventional cytology, manual reading, cytology triage of ASCUS (*N*=74 522)                  ThinPrep LBC, manual reading, cytology triage of ASCUS (*N*=20 921)                         ThinPrep LBC, ThinPrep Imaging System, cytology triage of ASCUS (*N*=33 614)                                                             Not relevant                                                                                                        Not relevant
  ⩾ASCUS                                                                                     3423 (5%)                                                                                     **536 (3%)**                                                                                    **1087 (3%)**                                                                                                 ---                                                                                                                ---
  CIN2                                                                                      183 (0.25%)                                                                                   **31 (0.15%)**                                                                                  **106 (0.32%)**                                                                                                ---                                                                                                                ---
  ⩾CIN3                                                                                     557 (0.75%)                                                                                    163 (0.78%)                                                                                      249 (0.74%)                                                                                                  ---                                                                                                                ---
  CIN treatments                                                                             826 (1.1%)                                                                                     219 (1.0%)                                                                                      389 (1.2%)                                                                                                   ---                                                                                                                ---
  \<CIN2                                                                                    1507 (2.02%)                                                                                 **215 (1.03%)**                                                                                  **433 (1.29%)**                                                                                                ---                                                                                                                ---
  False positive for ⩾CIN2                                                                  1683 (3.6%)                                                                                   **342 (1.6%)**                                                                                  **732 (2.2%)**                                                                                                 ---                                                                                                                ---
  False positive for ⩾CIN3                                                                  2866 (3.8%)                                                                                   **373 (1.8%)**                                                                                  **838 (2.5%)**                                                                                                 ---                                                                                                                ---
  PPV for ⩾CIN2                                                                                 22%                                                                                          **36%**                                                                                            33%                                                                                                      ---                                                                                                                ---
  PPV for ⩾CIN3                                                                                 16%                                                                                          **30%**                                                                                          **23%**                                                                                                    ---                                                                                                                ---

Abbreviations: ASCUS=atypical squamous cells of undetermined significance; CI=confidence interval; CIN=cervical intraepithelial neoplasia; HC2= Hybrid Capture 2; LBC=liquid-based cytology; PPV=positive predictive value; RP=relative proportion; triage=in case of ASCUS at age ⩾30 years.

Bold signifies significant change comparing the current phase with the most recent preceding phase, based on 95% CI for the calculated RP.

In women aged 23--59 years, by laboratory and phase.

###### Effect of full implementation of SurePath/FocalPoint or ThinPrep LBC and computer-assisted reading (last phase)[a](#t3-fn3){ref-type="fn"}

                                           No change (Roskilde)[b](#t3-fn4){ref-type="fn"}                                    SurePath (Hvidovre \[CPH M\])[c](#t3-fn5){ref-type="fn"}                                      ThinPrep (Odense)[d](#t3-fn6){ref-type="fn"}
  -------------------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------
  Before                      Baseline: Conventional cytology, manual reading, cytology triage of ASCUS               Baseline: conventional cytology, manual reading, cytology triage of ASCUS               Baseline: Conventional cytology, manual reading, cytology triage of ASCUS
  After                                                       As above                                    SurePath LBC, FocalPoint Slide Profiler 25% cutoff+FocalPoint Imaging System, HC2 triage of ASCUS        ThinPrep LBC, ThinPrep Imaging System, cytology triage of ASCUS
  **23--59 years**                                          47 300/53 979                                                                           23 849/62 644                                                                           33 614/74 522
  ⩾ASCUS                                            1012/1173, 0.98 (0.91--1.07)                                                          **1742/2299, 1.99 (1.87--2.11)**                                                        **1087/3423, 0.70 (0.66--0.75)**
  CIN2                                                85/118, 0.82 (0.62--1.09)                                                            **162/230, 1.85 (1.51--2.26)**                                                          **106/183, 1.28 (1.01--1.63)**
  ⩾CIN3                                              271/281, 1.10 (0.93--1.30)                                                            **394/624, 1.66 (1.46--1.88)**                                                            249/557, 0.99 (0.85--1.15)
  CIN treatments                                     405/482, 0.96 (0.84--1.09)                                                            **603/857, 1.85 (1.67--2.05)**                                                            389/826, 1.04 (0.93--1.18)
  \<CIN2                                           **323/471, 0.78 (0.68--0.90)**                                                          **581/722, 2.11 (1.90--2.36)**                                                          **433/1507; 0.64 (0.57--0.71)**
  False positive for ⩾CIN2                           656/774, 0.97 (0.87--1.07)                                                           **1186/1445, 2.16 (2.00--2.32)**                                                         **732/2683, 0.60 (0.56--0.66)**
  False positive for ⩾CIN3                           741/892, 0.95 (0.86--1.04)                                                           **1348/1675, 2.11 (1.97--2.27)**                                                         **838/2866, 0.65 (0.60--0.70)**
  PPV for ⩾CIN2                                      35%/34%, 1.03 (0.92--1.16)                                                            **32%/37%, 0.86 (0.79--0.94)**                                                          **33%/22%, 1.51 (1.36--1.68)**
  PPV for ⩾CIN3                                      27%/24%, 1.12 (0.97--1.29)                                                            **23%/27%, 0.83 (0.75--0.93)**                                                          **23%/16%, 1.41 (1.23--1.61)**
  **23--29 years**                                            5572/7350                                                                              8228/21 536                                                                             5310/14 299
  ⩾ASCUS                                             215/273, 1.04 (0.87--1.24)                                                            **815/1020, 2.09 (1.91--2.28)**                                                           435/1066, 1.10 (0.99--1.22)
  CIN2                                                22/38, 0.76 (0.45--1.29)                                                              **94/136, 1.81 (1.39--2.35)**                                                           **61/93, 1.77 (1.28--2.44)**
  ⩾CIN3                                               71/73, 1.28 (0.93--1.78)                                                             **204/288, 1.85 (1.55--2.21)**                                                            103/250, 1.11 (0.88--1.39)
  CIN treatments                                     103/133, 1.02 (0.79--1.32)                                                            **326/411, 2.08 (1.80--2.40)**                                                          **167/373, 1.21 (1.01--1.44)**
  \<CIN2                                              49/91, 0.71 (0.50--1.00)                                                             **258/258, 2.62 (2.21--3.10)**                                                            142/372, 1.03 (0.85--1.24)
  False positive for ⩾CIN2                           122/162, 0.99 (0.79--1.25)                                                            **517/596, 2.27 (2.02--2.55)**                                                            271/723, 1.01 (0.88--1.16)
  False positive for ⩾CIN3                           144/200, 0.95 (0.77--1.17)                                                            **611/732, 2.18 (1.97--2.43)**                                                            332/816, 1.10 (0.97--1.24)
  PPV for ⩾CIN2                                      43%/41%, 1.06 (0.86--1.31)                                                            **37%/42%, 0.88 (0.78--0.99)**                                                          **38%/32%, 1.17 (1.01--1.36)**
  PPV for ⩾CIN3                                      33%/27%, 1.23 (0.94--1.62)                                                              25%/28%, 0.89 (0.76--1.03)                                                              24%/23%, 1.01 (0.83--1.23)
  **30--44 years**                                          21 827/23 376                                                                           10 081/24 753                                                                           14 370/32 819
  ⩾ASCUS                                             544/548, 1.06 (0.95--1.20)                                                            **664/864, 1.89 (1.71--2.08)**                                                          **472/1435, 0.75 (0.68--0.83)**
  CIN2                                                49/66, 0.80 (0.55--1.15)                                                              **62/84, 1.81 (1.31--2.51)**                                                              33/73, 1.03 (0.68--1.56)
  ⩾CIN3                                              161/165, 1.05 (0.84--1.30)                                                            **176/273, 1.58 (1.31--1.91)**                                                            132/259, 1.16 (0.94--1.43)
  CIN treatments                                     244/275, 0.95 (0.80--1.13)                                                            **252/360, 1.72 (1.47--2.02)**                                                            188/367, 1.17 (0.98--1.39)
  \<CIN2                                             168/190, 0.95 (0.77--1.16)                                                            **238/258, 2.27 (1.90--2.70)**                                                          **181/579, 0.71 (0.60--0.84)**
  False positive for ⩾CIN2                           334/317, 1.13 (0.97--1.31)                                                            **426/507, 2.06 (1.82--2.34)**                                                          **307/1103, 0.64 (0.56--0.72)**
  False positive for ⩾CIN3                           383/383, 1.07 (0.93--1.23)                                                            **488/591, 2.03 (1.80--2.28)**                                                          **340/1176, 0.66 (0.59--0.74)**
  PPV for ⩾CIN2                                      39%/42%, 0.92 (0.79--1.06)                                                            **36%/41%, 0.87 (0.76--0.99)**                                                          **35%/23%, 1.51 (1.29--1.76)**
  PPV for ⩾CIN3                                      30%/30%, 0.98 (0.82--1.18)                                                            **27%/32%, 0.84 (0.71--0.98)**                                                          **28%/18%, 1.55 (1.29--1.86)**
  **45--59 years**                                          19 901/23 253                                                                            5540/16 355                                                                            13 934/27 404
  ⩾ASCUS                                           **253/352, 0.84 (0.72--0.99)**                                                          **263/415, 1.87 (1.61--2.18)**                                                          **180/922, 0.38 (0.33--0.45)**
  CIN2                                                14/14, 1.17 (0.56--2.45)                                                                 6/10, 1.77 (0.64--4.87)                                                                12/17, 1.39 (0.66--2.91)
  ⩾CIN3                                               39/43, 1.06 (0.69--1.63)                                                                14/63, 0.66 (0.37--1.17)                                                                14/48, 0.57 (0.32--1.04)
  CIN treatments                                      58/74, 0.92 (0.65--1.29)                                                                25/86, 0.86 (0.55--1.34)                                                                34/86, 0.78 (0.52--1.16)
  \<CIN2                                           **106/190, 0.65 (0.51--0.83)**                                                             85/206, 1.22 (0.95--1.57)                                                            **110/556, 0.39 (0.32--0.48)**
  False positive for ⩾CIN2                         **200/295, 0.79 (0.66--0.95)**                                                          **243/342, 2.10 (1.78--2.47)**                                                          **154/857, 0.35 (0.30--0.42)**
  False positive for ⩾CIN3                         **214/309, 0.81 (0.68--0.96)**                                                          **249/352, 2.09 (1.78--2.45)**                                                          **166/874, 0.37 (0.32--0.44)**
  PPV for ⩾CIN2                                      21%/16%, 1.29 (0.92--1.81)                                                             **8%/18%, 0.43 (0.27--0.69)**                                                           **14%/7%, 2.05 (1.34--3.14)**
  PPV for ⩾CIN3                                      15%/12%, 1.26 (0.84--1.89)                                                             **5%/15%, 0.35 (0.20--0.61)**                                                             8%/5%, 1.49 (0.84--2.65)

Abbreviations: ASCUS=atypical squamous cells of undetermined significance; CI=confidence interval; CIN=cervical intraepithelial neoplasia; CPH M=Copenhagen Municipality; HC2=Hybrid Capture 2; *N*~after~=last phase; *N*~before~=phase 1; PPV=positive predictive value; RP=relative proportion; triage=in case of ASCUS at age ⩾30 years.

Bold signifies significant change comparing the last phase ('after\') with phase 1 ('before\').

Compared with manually read conventional cytology (baseline).

*N*~after~/*N*~before~, RR (95% CI).

*N*~after~/*N*~before~, RR (95% CI).

*N*~after~/*N*~before~, RR (95% CI).

###### Completeness of 2.5-year follow-up after an ⩾ASCUS primary sample[a](#tA1-fn2){ref-type="fn"}

                                                                  Phase 1                             Phase 2               Phase 3                Phase 4               Phase 5
  ------------------------------------------ ------------------------------------------------- --------------------- ---------------------- --------------------- ---------------------
  **Included samples/all primary samples**                                                                                                                        
  Roskilde                                                  53 979/56 769 (95%)                 49 856/51 902 (96%)   47 300/48 717 (97%)            ---                   ---
  Hvidovre (CPH M)                                          62 644/73 551 (85%)                 59 274/67 311 (88%)   94 541/105 483 (90%)   43 002/47 164 (91%)   23 849/25 587 (93%)
  Hvidovre (FRB M)                                                  ---                          9385/10 540 (89%)    17 643/19 567 (90%)      7018/7639 (92%)       4794/5142 (93%)
  Hillerød                                                          ---                         28 888/29 928 (97%)   24 593/25 631 (96%)    18 434/19 178 (96%)           ---
  Odense                                      74 522/76 528 (97%)[b](#tA1-fn3){ref-type="fn"}   20 921/21 251 (98%)   33 614/34 066 (99%)            ---                   ---
  **No follow-up/⩾ASCUS**                                                                                                                                         
  Roskilde                                                     78/1173 (7%)                        64/1251 (5%)           51/1012 (5%)               ---                   ---
  Hvidovre (CPH M)                                             111/2299 (5%)                       87/2307 (4%)          343/4832 (7%)          257/2751 (9%)         120/1742 (7%)
  Hvidovre (FRB M)                                                  ---                             9/361 (2%)            56/830 (7%)           43/420 (10%)           23/352 (7%)
  Hillerød                                                          ---                             22/878 (3%)           26/865 (3%)            30/843 (4%)               ---
  Odense                                         83/3423 (2%)[c](#tA1-fn4){ref-type="fn"}           19/536 (4%)           57/1087 (5%)               ---                   ---
  **No histology follow-up/⩾ASCUS**                                                                                                                               
  Roskilde                                                    225/1173 (19%)                      355/1251 (28%)         282/1012 (28%)              ---                   ---
  Hvidovre (CPH M)                                            612/2299 (27%)                      671/2307 (29%)        1504/4832 (31%)        767/2751 (28%)        485/1742 (28%)
  Hvidovre (FRB M)                                                  ---                            116/361 (32%)         263/830 (32%)          114/420 (27%)         88/352 (25%)
  Hillerød                                                          ---                            320/878 (36%)         287/865 (33%)          280/843 (33%)              ---
  Odense                                        1093/3423 (32%)[d](#tA1-fn5){ref-type="fn"}        108/536 (20%)         242/1087 (22%)              ---                   ---

Abbreviations: ASCUS=atypical squamous cells of undetermined significance; CPH M=Copenhagen Municipality; FRB M=Frederiksberg Municipality.

Primary screening samples included in the study, by laboratory and phase, women aged 23--59 years.

Phase 1a: 29 293/30 280 (97%). Phase 1b: 45 229/46 248 (98%).

Phase 1a: 47/1374 (3%). Phase 1b: 36/2049 (2%).

Phase 1a: 453/1374 (33%). Phase 1b: 640/2049 (31%).

###### Distribution of age groups by phase and laboratory

                             Phase 1         Phase 2         Phase 3         Phase 4         Phase 5
  ---------------------- --------------- --------------- --------------- --------------- ---------------
  **Roskilde**                                                                           
  23--29 years             7350 (14%)      6346 (13%)      5572 (12%)          ---             ---
  30--44 years            23 376 (43%)    21 843 (44%)    21 827 (46%)         ---             ---
  45--59 years            23 253 (43%)    21 667 (43%)    19 901 (42%)         ---             ---
  Total                   53 797 (100%)   49 856 (100%)   47 300 (100%)        ---             ---
  Mean age (s.d.)          41.8 (10.1)     42.3 (10.2)     42.2 (10.0)         ---             ---
  **Hvidovre (CPH M)**                                                                   
  23--29 years            21 536 (34%)    21 537 (36%)    33 450 (35%)    13 733 (32%)     8228 (35%)
  30--44 years            24 753 (40%)    21 987 (37%)    37 576 (40%)    18 348 (43%)    10 081 (42%)
  45--59 years            16 355 (26%)    15 750 (27%)    23 515 (25%)    10 921 (25%)     5540 (23%)
  Total                   62 644 (100%)   59 274 (100%)   94 541 (100%)   43 002 (100%)   23 849 (100%)
  Mean age (s.d.)          36.4 (10.4)     36.4 (10.7)     36.3 (10.6)     36.7 (10.4)     36.1 (10.4)
  **Hvidove (FRB M)**                                                                    
  23--29 years                 ---         2413 (26%)      4949 (28%)      1909 (27%)      1238 (26%)
  30--44 years                 ---         3683 (39%)      7225 (41%)      3071 (44%)      2164 (45%)
  45--59 years                 ---         3289 (35%)      5460 (31%)      2038 (29%)      1392 (29%)
  Total                        ---         9385 (100%)    17 634 (100%)    7018 (100%)     4794 (100%)
  Mean age (s.d.)              ---         39.1 (11.0)     38.3 (11.0)     38.0 (10.8)     38.2 (10.7)
  **Hillerød**                                                                           
  23--29 years                 ---          2637 (9%)      2725 (11%)      1836 (10%)          ---
  30--44 years                 ---        13 342 (46%)    11 043 (45%)     8541 (46%)          ---
  45--59 years                 ---        12 909 (45%)    10 825 (44%)     8057 (44%)          ---
  Total                        ---        28 888 (100%)   24 593 (100%)   18 434 (100%)        ---
  Mean age (s.d.)              ---         42.9 (9.6)      42.7 (10.0)     42.7 (9.6)          ---
  **Odense**                                                                             
  23--29 years            14 299 (19%)     3075 (15%)      5310 (16%)          ---             ---
  30--44 years            32 819 (44%)     9342 (45%)     14 370 (43%)         ---             ---
  45--59 years            27 404 (37%)     8504 (41%)     13 934 (41%)         ---             ---
  Total                   74 522 (100%)   20 921 (100%)   33 614 (100%)        ---             ---
  Mean age (s.d.)          40.1 (10.4)     41.4 (10.2)     41.5 (10.3)         ---             ---

Abbreviations: CPH M=Copenhagen Municipality; FRB M=Frederiksberg Municipality.

###### Laboratory with manual reading of conventional cytology throughout the study period (Roskilde)[a](#tA3-fn3){ref-type="fn"}

                                              Phase 2 (baseline) *vs* phase 1 (baseline)                        Phase 3 (baseline) *vs* phase 2 (baseline)
  -------------------------------- ----------------------------------------------------------------- -----------------------------------------------------------------
  Change in the technology                                       None                                                              None
  Same technology in both phases    Conventional cytology, manual reading, cytology triage of ASCUS   Conventional cytology, manual reading, cytology triage of ASCUS
  **23--59 years**                                           49 856/53 979                                                     47 300/49 856
  ⩾ASCUS                                           **1251/1173, 1.15 (1.07--1.25)**                                  **1012/1251, 0.85 (0.79--0.93)**
  CIN2                                                104/118, 0.95 (0.73--1.24)                                         85/104, 0.86 (0.65--1.15)
  ⩾CIN3                                               289/281, 1.11 (0.95--1.31)                                        271/289, 0.99 (0.84--1.17)
  CIN treatments                                      491/482, 1.10 (0.97--1.25)                                      **405/491, 0.87 (0.76--0.99)**
  \<CIN2                                              439/471, 1.01 (0.89--1.15)                                      **323/439, 0.78 (0.67--0.89)**
  False positive for ⩾CIN2                          **858/774, 1.20 (1.09--1.32)**                                    **656/858, 0.81 (0.73--0.89)**
  False positive for ⩾CIN3                          **962/892, 1.17 (1.07--1.28)**                                    **741/962, 0.81 (0.74--0.89)**
  PPV for ⩾CIN2                                       31%/34%, 0.92 (0.82--1.04)                                        35%/31%, 1.12 (1.00--1.26)
  PPV for ⩾CIN3                                       23%/24%, 0.96 (0.84--1.11)                                      **27%/23%, 1.16 (1.00--1.34)**
  **23--29 years**                                             6346/7350                                                         5572/6346
  ⩾ASCUS                                              254/273, 1.08 (0.91--1.27)                                        215/254, 0.96 (0.81--1.15)
  CIN2                                                 24/38, 0.73 (0.44--1.22)                                          22/24, 1.04 (0.59--1.86)
  ⩾CIN3                                                75/73, 1.19 (0.86--1.64)                                          71/75, 1.08 (0.78--1.49)
  CIN treatments                                      119/133, 1.04 (0.81--1.32)                                        103/119, 0.99 (0.76--1.28)
  \<CIN2                                               77/91, 0.98 (0.72--1.33)                                          49/77, 0.72 (0.51--1.04)
  False positive for ⩾CIN2                            155/162, 1.11 (0.89--1.38)                                        122/155, 0.90 (0.71--1.13)
  False positive for ⩾CIN3                            179/200, 1.04 (0.85--1.26)                                        144/179, 0.92 (0.74--1.14)
  PPV for ⩾CIN2                                       39%/41%, 0.96 (0.78--1.18)                                        43%/39%, 1.11 (0.89--1.38)
  PPV for ⩾CIN3                                       30%/27%, 1.10 (0.84--1.45)                                        33%/30%, 1.12 (0.85--1.46)
  **30--44 years**                                           21 843/23 376                                                     21 827/21 843
  ⩾ASCUS                                            **630/548, 1.23 (1.10--1.38)**                                    **544/630, 0.86 (0.77--0.97)**
  CIN2                                                 72/66, 1.17 (0.84--1.63)                                        **49/72, 0.68 (0.47--0.98)**
  ⩾CIN3                                               180/165, 1.17 (0.95--1.44)                                        161/180, 0.90 (0.72--1.11)
  CIN treatments                                    **305/375, 1.19 (1.01--1.40)**                                    **244/305, 0.80 (0.68--0.95)**
  \<CIN2                                              195/190, 1.10 (0.90--1.34)                                        168/195, 0.86 (0.70--1.06)
  False positive for ⩾CIN2                          **378/317, 1.28 (1.10--1.48)**                                      334/378, 0.88 (0.76--1.02)
  False positive for ⩾CIN3                          **450/383, 1.26 (1.10--1.44)**                                    **383/450, 0.85 (0.74--0.97)**
  PPV for ⩾CIN2                                       40%/42%, 0.95 (0.83--1.09)                                        39%/40%, 0.97 (0.84--1.11)
  PPV for ⩾CIN3                                       29%/30%, 0.95 (0.79--1.13)                                        30%/29%, 1.04 (0.87--1.24)
  **45--59 years**                                           21 667/23 253                                                     19 901/21 667
  ⩾ASCUS                                              367/352, 1.12 (0.97--1.29)                                      **253/367, 0.75 (0.64--0.88)**
  CIN2                                                  8/14, 0.61 (0.26--1.46)                                           14/8, 1.91 (0.80--4.54)
  ⩾CIN3                                                34/43, 0.85 (0.54--1.33)                                          39/34, 1.25 (0.79--1.98)
  CIN treatments                                       67/74, 0.97 (0.70--1.35)                                          58/67, 0.94 (0.66--1.34)
  \<CIN2                                              167/190, 0.94 (0.77--1.16)                                      **106/167, 0.69 (0.54--0.88)**
  False positive for ⩾CIN2                          **325/295, 1.18 (1.01--1.38)**                                    **200/325, 0.67 (0.56--0.80)**
  False positive for ⩾CIN3                            333/309, 1.16 (0.99--1.35)                                      **214/333, 0.70 (0.59--0.83)**
  PPV for ⩾CIN2                                       11%/16%, 0.71 (0.49--1.02)                                      **21%/11%, 1.83 (1.26--2.66)**
  PPV for ⩾CIN3                                        9%/12%, 0.76 (0.50--1.16)                                       **15%/9%, 1.66 (1.08--2.56)**

Abbreviations: ASCUS=atypical squamous cells of undetermined significance; CIN=cervical intraepithelial neoplasia; PPV=positive predictive value; triage=in case of ASCUS at age ⩾30 years.

Bold signifies significant change comparing the two phases.

Comparison of outcomes, by age group and phase.

###### Laboratory with SurePath cytological technology (Hvidovre/Copenhagen Municipality)[a](#tA4-fn3){ref-type="fn"}

                                                 Phase 2 *vs* phase 1                                      Phase 3 *vs* phase 2                                                 Phase 4 *vs* phase 3                                                     Phase 5 *vs* phase 4
  -------------------------------- ------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------
  Change in the technology               FocalPoint Slide Profiler 50% cutoff                                  SurePath LBC                            FocalPoint Slide Profiler cutoff decreased to 25%, HC2 triage of ASCUS                        FocalPoint GS Imaging System
  Same technology in both phases    Conventional cytology, cytology triage of ASCUS   FocalPoint Slide Profiler 50% cutoff, cytology triage of ASCUS                                SurePath LBC                                SurePath LBC, FocalPoint Slide Profiler 25% cutoff, HC2 triage of ASCUS
  **23--59 years**                                   59 274/62 644                                            94 541/59 274                                                        43 002/94 541                                                             23 849/43 002
  ⩾ASCUS                                     2307/2299, 1.06 (1.00--1.12)                            **4832/2307, 1.31 (1.25--1.38)**                                     **2751/4832, 1.25 (1.20--1.31)**                                         **1742/2751, 1.14 (1.08--1.21)**
  CIN2                                        201/230, 0.92 (0.76--1.12)                              **423/201, 1.32 (1.12--1.56)**                                       **242/423, 1.26 (1.07--1.47)**                                             162/242, 1.21 (0.99--1.47)
  ⩾CIN3                                       547/624, 0.93 (0.83--1.04)                             **1148/547, 1.32 (1.19--1.46)**                                      **641/1148, 1.23 (1.12--1.35)**                                             394/641, 1.11 (0.98--1.26)
  CIN treatments                              828/857, 1.02 (0.93--1.12)                             **1780/828, 1.35 (1.24--1.46)**                                      **959/1780, 1.18 (1.10--1.28)**                                           **603/959, 1.13 (1.03--1.25)**
  \<CIN2                                    **801/722, 1.17 (1.06--1.30)**                           **1414/801, 1.11 (1.02--1.21)**                                      **844/1414, 1.31 (1.21--1.43)**                                           **581/844, 1.24 (1.12--1.38)**
  False positive for ⩾CIN2                 **1559/1445, 1.14 (1.06--1.22)**                          **3261/1559, 1.31 (1.24--1.39)**                                     **1868/3261, 1.26 (1.19--1.33)**                                         **1186/1868, 1.14 (1.07--1.23)**
  False positive for ⩾CIN3                 **1760/1675, 1.11 (1.04--1.19)**                          **3684/1760, 1.31 (1.24--1.39)**                                     **2110/3684, 1.26 (1.20--1.33)**                                         **1348/2110, 1.15 (1.08--1.23)**
  PPV for ⩾CIN2                             **32%/37%, 0.87 (0.81--0.94)**                              33%/32%, 1.00 (0.93--1.08)                                           32%/33%, 0.99 (0.92--1.06)                                               32%/32%, 0.99 (0.91--1.09)
  PPV for ⩾CIN3                             **24%/27%, 0.87 (0.79--0.96)**                              24%/24%, 1.00 (0.92--1.10)                                           23%/24%, 0.98 (0.90--1.07)                                               23%/23%, 0.97 (0.87--1.08)
  **23--29 years**                                   21 537/21 536                                            33 450/21 537                                                        13 733/33 450                                                              8228/13 733
  ⩾ASCUS                                   **1119/1020, 1.10 (1.01--1.19)**                          **2590/1119, 1.49 (1.39--1.60)**                                     **1279/2590, 1.20 (1.13--1.28)**                                            815/1279, 1.06 (0.98--1.16)
  CIN2                                        120/136, 0.88 (0.69--1.13)                              **251/120, 1.35 (1.08--1.67)**                                       **134/251, 1.30 (1.06--1.60)**                                              94/134, 1.17 (0.90--1.52)
  ⩾CIN3                                       291/288, 1.01 (0.86--1.19)                              **629/291, 1.39 (1.21--1.60)**                                       **316/629, 1.22 (1.07--1.40)**                                             204/316, 1.08 (0.91--1.28)
  CIN treatments                              449/411, 1.09 (0.96--1.25)                              **996/449, 1.43 (1.28--1.59)**                                       **476/996, 1.16 (1.05--1.30)**                                             326/476, 1.14 (1.00--1.31)
  \<CIN2                                    **346/258, 1.34 (1.14--1.57)**                            **704/346, 1.31 (1.15--1.49)**                                       **335/704, 1.16 (1.02--1.32)**                                           **258/335, 1.29 (1.10--1.51)**
  False positive for ⩾CIN2                  **708/596, 1.19 (1.07--1.32)**                           **1710/708, 1.56 (1.43--1.69)**                                      **829/1710, 1.18 (1.09--1.28)**                                             517/829, 1.04 (0.94--1.16)
  False positive for ⩾CIN3                  **828/732, 1.13 (1.03--1.25)**                           **1961/828, 1.52 (1.41--1.65)**                                      **963/1961, 1.20 (1.11--1.29)**                                             611/963, 1.06 (0.96--1.17)
  PPV for ⩾CIN2                             **37%/42%, 0.88 (0.79--0.98)**                              34%/37%, 0.93 (0.84--1.02)                                           35%/34%, 1.04 (0.94--1.14)                                               37%/35%, 1.04 (0.92--1.17)
  PPV for ⩾CIN3                               26%/28%, 0.92 (0.80--1.06)                                24%/26%, 0.93 (0.83--1.05)                                           25%/24%, 1.02 (0.90--1.14)                                               25%/25%, 1.01 (0.87--1.18)
  **30--44 years**                                   21 987/24 753                                            37 576/21 987                                                        18 348/37 576                                                             10 081/18 348
  ⩾ASCUS                                      764/864, 1.00 (0.90--1.10)                             **1690/764, 1.29 (1.19--1.41)**                                      **1035/1690, 1.25 (1.16--1.35)**                                          **664/1035, 1.17 (1.06--1.28)**
  CIN2                                         63/84, 0.84 (0.61--1.17)                               **154/63, 1.43 (1.07--1.92)**                                        **98/154, 1.30 (1.01--1.68)**                                               62/98, 1.15 (0.84--1.58)
  ⩾CIN3                                       217/273, 0.89 (0.75--1.07)                              **475/217, 1.28 (1.09--1.50)**                                       **291/475, 1.25 (1.09--1.45)**                                             176/291, 1.10 (0.91--1.33)
  CIN treatments                              308/360, 0.96 (0.83--1.12)                              **702/308, 1.33 (1.17--1.52)**                                       **430/702, 1.25 (1.11--1.41)**                                             252/430, 1.07 (0.91--1.24)
  \<CIN2                                      245/258, 1.07 (0.90--1.27)                                451/245, 1.08 (0.92--1.26)                                         **361/451, 1.64 (1.43--1.88)**                                           **238/361, 1.20 (1.02--1.41)**
  False positive for ⩾CIN2                    484/507, 1.07 (0.95--1.22)                             **1061/484, 1.28 (1.15--1.43)**                                      **646/1061, 1.25 (1.13--1.37)**                                           **426/646, 1.20 (1.06--1.35)**
  False positive for ⩾CIN3                    547/591, 1.04 (0.93--1.17)                             **1215/547, 1.30 (1.18--1.44)**                                      **744/1215, 1.25 (1.15--1.37)**                                           **488/744, 1.19 (1.07--1.33)**
  PPV for ⩾CIN2                               37%/41%, 0.89 (0.78--1.00)                                37%/37%, 1.02 (0.91--1.14)                                           38%/37%, 1.01 (0.91--1.12)                                               36%/38%, 0.95 (0.84--1.08)
  PPV for ⩾CIN3                               28%/32%, 0.90 (0.77--1.04)                                28%/28%, 0.99 (0.86--1.13)                                           28%/28%, 1.00 (0.88--1.13)                                               27%/28%, 0.94 (0.80--1.11)
  **45--59 years**                                   15 750/16 355                                            23 515/15 750                                                        10 921/23 515                                                              5540/10 921
  ⩾ASCUS                                      424/415, 1.06 (0.93--1.21)                              **552/424, 0.87 (0.77--0.99)**                                       **437/552, 1.70 (1.51--1.93)**                                           **263/437, 1.19 (1.02--1.38)**
  CIN2                                         18/10, 1.87 (0.86--4.05)                                  18/18, 0.67 (0.35--1.29)                                             10/18, 1.20 (0.55--2.59)                                                  6/10, 1.18 (0.43--3.25)
  ⩾CIN3                                      **39/63, 0.64 (0.43--0.96)**                                44/39, 0.76 (0.49--1.16)                                           **34/44, 1.66 (1.06--2.60)**                                               14/34, 0.81 (0.44--1.51)
  CIN treatments                               71/86, 0.86 (0.63--1.17)                                  82/71, 0.77 (0.56--1.06)                                             53/82, 1.39 (0.99--1.96)                                                 25/53, 0.93 (0.58--1.49)
  \<CIN2                                      210/206, 1.06 (0.87--1.28)                              **259/210, 0.83 (0.69--0.99)**                                       **148/259, 1.23 (1.01--1.50)**                                              85/148, 1.13 (0.87--1.48)
  False positive for ⩾CIN2                    367/342, 1.11 (0.96--1.29)                                490/367, 0.89 (0.78--1.02)                                         **393/490, 1.73 (1.52--1.97)**                                           **243/393, 1.22 (1.04--1.43)**
  False positive for ⩾CIN3                    385/352, 1.14 (0.98--1.31)                                508/385, 0.88 (0.78--1.01)                                         **403/508, 1.71 (1.50--1.94)**                                           **249/403, 1.22 (1.04--1.42)**
  PPV for ⩾CIN2                               13%/18%, 0.76 (0.56--1.05)                                11%/13%, 0.84 (0.60--1.17)                                           10%/11%, 0.90 (0.62--1.29)                                                8%/10%, 0.76 (0.46--1.25)
  PPV for ⩾CIN3                              **9%/15%, 0.61 (0.42--0.88)**                               8%/9%, 0.87 (0.57--1.31)                                             8%/8%, 0.98 (0.64--1.50)                                                 5%/8%, 0.68 (0.37--1.25)

Abbreviations: ASCUS=atypical squamous cells of undetermined significance; CIN=cervical intraepithelial neoplasia; HC2=Hybrid Capture 2; PPV=positive predictive value; triage=in case of ASCUS at age ⩾30 years.

Bold signifies significant change comparing the two phases.

Comparison of outcomes, by age group and phase.

###### Laboratory with SurePath cytological technology (Hvidovre/Frederiksberg Municipality)[a](#tA5-fn3){ref-type="fn"}

                                                         Phase 3 *vs* phase 2                                                 Phase 4 *vs* phase 3                                                     Phase 5 *vs* phase 4
  -------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------
  Change in the technology                                   SurePath LBC                            FocalPoint Slide Profiler cutoff decreased to 25%, HC2 triage of ASCUS                        FocalPoint GS Imaging System
  Same technology in both phases    FocalPoint Slide Profiler 50% cutoff, cytology triage of ASCUS                                SurePath LBC                                SurePath LBC, FocalPoint Slide Profiler 25% cutoff, HC2 triage of ASCUS
  **23--59 years**                                           17 634/9385                                                          7018/17 634                                                                4794/7018
  ⩾ASCUS                                            **830/361, 1.22 (1.08--1.38)**                                       **420/830, 1.27 (1.13--1.43)**                                           **352/420, 1.23 (1.07--1.41)**
  CIN2                                               **77/26, 1.58 (1.01--2.46)**                                         **51/77, 1.66 (1.17--2.37)**                                               39/51, 1.12 (0.74--1.70)
  ⩾CIN3                                               195/97, 1.07 (0.84--1.36)                                          **107/195, 1.38 (1.09--1.74)**                                              80/107, 1.09 (0.82--1.46)
  CIN treatments                                      304/134, 1.21 (0.99--1.48)                                         **169/304, 1.40 (1.16--1.68)**                                             140/169, 1.21 (0.97--1.51)
  \<CIN2                                              239/113, 1.13 (0.90--1.41)                                           105/239, 1.10 (0.88--1.39)                                             **122/105, 1.70 (1.31--2.20)**
  False positive for ⩾CIN2                          **558/238, 1.25 (1.07--1.45)**                                       **262/558, 1.18 (1.02--1.36)**                                           **233/262, 1.30 (1.10--1.55)**
  False positive for ⩾CIN3                          **635/264, 1.28 (1.11--1.47)**                                       **313/635, 1.24 (1.08--1.41)**                                           **272/313, 1.27 (1.09--1.49)**
  PPV for ⩾CIN2                                       33%/34%, 0.96 (0.81--1.14)                                           38%/33%, 1.15 (0.98--1.34)                                               34%/38%, 0.90 (0.74--1.09)
  PPV for CIN3                                        23%/27%, 0.87 (0.71--1.08)                                           25%/23%, 1.08 (0.88--1.33)                                               23%/25%, 0.89 (0.69--1.15)
  **23--29 years**                                            4949/2413                                                            1909/4949                                                                 1238/1909
  ⩾ASCUS                                            **367/133, 1.35 (1.11--1.63)**                                       **174/367, 1.23 (1.03--1.46)**                                             135/174, 1.20 (0.97--1.48)
  CIN2                                                 45/19, 1.15 (0.68--1.97)                                             21/45, 1.21 (0.72--2.03)                                                 24/21, 1.76 (0.99--3.15)
  ⩾CIN3                                                97/36, 1.31 (0.90--1.92)                                           **56/97, 1.50 (1.08--2.07)**                                               37/56, 1.02 (0.68--1.53)
  CIN treatments                                    **156/55, 1.38 (1.02--1.87)**                                        **81/156, 1.35 (1.03--1.75)**                                               66/81, 1.26 (0.92--1.73)
  \<CIN2                                               92/30, 1.50 (0.99--2.25)                                             34/92, 0.96 (0.65--1.41)                                               **38/34, 1.72 (1.09--2.72)**
  False positive for ⩾CIN2                          **225/78, 1.41 (1.09--1.81)**                                          97/225, 1.12 (0.89--1.41)                                                 74/97, 1.18 (0.88--1.58)
  False positive for ⩾CIN3                          **270/97, 1.36 (1.08--1.70)**                                          118/270, 1.13 (0.92--1.40)                                                98/118, 1.28 (0.99--1.66)
  PPV for ⩾CIN2                                       39%/41%, 0.94 (0.74--1.19)                                           44%/39%, 1.14 (0.93--1.41)                                               45%/44%, 1.02 (0.80--1.31)
  PPV for CIN3                                        26%/27%, 0.98 (0.70--1.35)                                           32%/26%, 1.22 (0.92--1.60)                                               27%/32%, 0.85 (0.60--1.21)
  **30--44 years**                                            7225/3683                                                            3071/7225                                                                 2164/3071
  ⩾ASCUS                                            **334/136, 1.25 (1.03--1.52)**                                       **176/334, 1.24 (1.04--1.48)**                                             151/176, 1.22 (0.99--1.50)
  CIN2                                               **31/5, 3.16 (1.23--8.12)**                                          **28/31, 2.12 (1.28--3.54)**                                               13/28, 0.66 (0.34--1.27)
  ⩾CIN3                                                82/44, 0.95 (0.66--1.37)                                           **50/82, 1.43 (1.01--2.03)**                                               42/50, 1.19 (0.79--1.79)
  CIN treatments                                      129/55, 1.20 (0.87--1.64)                                          **85/129, 1.55 (1.18--2.03)**                                               67/85, 1.12 (0.82--1.53)
  \<CIN2                                               94/42, 1.14 (0.79--1.64)                                             49/94, 1.23 (0.87--1.73)                                               **60/49, 1.74 (1.20--2.52)**
  False positive for ⩾CIN2                          **221/87, 1.29 (1.01--1.65)**                                          98/221, 1.04 (0.83--1.32)                                               **96/98, 1.39 (1.05--1.83)**
  False positive for ⩾CIN3                          **252/92, 1.40 (1.10--1.77)**                                          126/252, 1.18 (0.95--1.45)                                             **109/126, 1.23 (0.96--1.58)**
  PPV for ⩾CIN2                                       34%/36%, 0.94 (0.72--1.23)                                         **44%/34%, 1.31 (1.05--1.64)**                                             36%/44%, 0.82 (0.63--1.07)
  PPV for CIN3                                        25%/32%, 0.76 (0.56--1.03)                                           28%/25%, 1.16 (0.86--1.56)                                               28%/28%, 0.98 (0.69--1.39)
  **45--59 years**                                            5460/3289                                                            2038/5460                                                                 1392/2038
  ⩾ASCUS                                              129/92, 0.84 (0.65--1.10)                                          **70/129, 1.45 (1.09--1.94)**                                               66/70, 1.38 (0.99--1.92)
  CIN2                                                  1/2, 0.30 (0.03--3.32)                                              2/1, 5.36 (0.49--59.06)                                                   2/2, 1.46 (0.21--10.38)
  ⩾CIN3                                                16/17, 0.57 (0.29--1.12)                                             1/16, 0.17 (0.02--1.26)                                                   1/1, 1.46 (0.09--23.39)
  CIN treatments                                     **19/24, 0.48 (0.26--0.87)**                                           3/19, 0.42 (0.13--1.43)                                                   7/3, 3.42 (0.88--13.19)
  \<CIN2                                               53/41, 0.78 (0.52--1.17)                                             22/53, 1.11 (0.68--1.82)                                                 24/22, 1.60 (0.90--2.84)
  False positive for ⩾CIN2                            112/73, 0.92 (0.69--1.24)                                          **67/112, 1.60 (1.19--2.16)**                                               63/67, 1.38 (0.98--1.93)
  False positive for ⩾CIN3                            113/75, 0.91 (0.68--1.21)                                          **69/113, 1.64 (1.22--2.20)**                                               65/69, 1.38 (0.99--1.92)
  PPV for ⩾CIN2                                       13%/21%, 0.64 (0.35--1.16)                                           4%/13%, 0.33 (0.10--1.07)                                                 5%/4%, 1.06 (0.22--5.07)
  PPV for CIN3                                        12%/18%, 0.67 (0.36--1.26)                                         **1%/12%, 0.12 (0.02--0.85)**                                               2%/1%, 1.06 (0.07--16.61)

Abbreviations: ASCUS=atypical squamous cells of undetermined significance; CIN=cervical intraepithelial neoplasia; HC2=Hybrid Capture 2; PPV=positive predictive value; triage=in case of ASCUS at age ⩾30 years.

Bold signifies significant change comparing the two phases.

Comparison of outcomes, by age group and phase.

###### Laboratory with SurePath cytological technology (Hillerød)[a](#tA6-fn3){ref-type="fn"}

                                                         Phase 3 *vs* phase 2                                                     Phase 4 *vs* phase 3
  -------------------------------- ----------------------------------------------------------------- -------------------------------------------------------------------------------
  Change in the technology          SurePath LBC, FocalPoint Slide Profiler cutoff decreased to 25%                           FocalPoint GS Imaging System
  Same technology in both phases                       Cytology triage of ASCUS                       SurePath LBC, Focal Point Slide Profiler 25% cutoff, cytology triage of ASCUS
  **23--59 years**                                           24 593/28 888                                                            18 434/24 593
  ⩾ASCUS                                            **865/878, 1.16 (1.06--1.27)**                                           **843/865, 1.30 (1.18--1.43)**
  CIN2                                                 71/67, 1.24 (0.89--1.74)                                               **77/71, 1.45 (1.05--2.00)**
  ⩾CIN3                                             **183/151, 1.42 (1.15--1.76)**                                           **181/183, 1.32 (1.08--1.62)**
  CIN treatments                                    **291/281, 1.22 (1.03--1.43)**                                           **280/291, 1.28 (1.09--1.51)**
  \<CIN2                                              298/318, 1.10 (0.94--1.29)                                             **275/298, 1.23 (1.05--1.45)**
  False positive for ⩾CIN2                            611/660, 1.09 (0.98--1.21)                                             **585/611, 1.28 (1.14--1.43)**
  False positive for ⩾CIN3                            682/727, 1.10 (0.99--1.22)                                             **662/682, 1.29 (1.17--1.44)**
  PPV for ⩾CIN2                                     **29%/25%, 1.18 (1.01--1.38)**                                             31%/29%, 1.04 (0.90--1.20)
  PPV for ⩾CIN3                                     **21%/17%, 1.23 (1.01--1.49)**                                             21%/21%, 1.01 (0.85--1.22)
  **23--29 years**                                             2725/2637                                                                1836/2725
  ⩾ASCUS                                            **163/110, 1.43 (1.13--1.82)**                                           **151/163, 1.37 (1.11--1.70)**
  CIN2                                                 18/15, 1.16 (0.59--2.30)                                               **27/18, 2.23 (1.23--4.03)**
  ⩾CIN3                                                49/31, 1.53 (0.98--2.39)                                               **51/49, 1.54 (1.05--2.28)**
  CIN treatments                                       71/52, 1.32 (0.93--1.88)                                               **80/71, 1.67 (1.22--2.29)**
  \<CIN2                                             **43/25, 1.66 (1.02--2.72)**                                               32/43, 1.10 (0.70--1.74)
  False positive for ⩾CIN2                           **96/64, 1.45 (1.06--1.98)**                                               73/96, 1.13 (0.84--1.52)
  False positive for ⩾CIN3                           **114/79, 1.40 (1.05--1.85)**                                             100/114, 1.30 (1.00--1.69)
  PPV for ⩾CIN2                                       41%/42%, 0.98 (0.74--1.31)                                               52%/41%, 1.26 (0.99--1.60)
  PPV for ⩾CIN3                                       30%/28%, 1.07 (0.73--1.56)                                               34%/30%, 1.12 (0.81--1.55)
  **30--44 years**                                           11 043/13 342                                                             8541/11 043
  ⩾ASCUS                                            **486/438, 1.34 (1.18--1.52)**                                           **462/486, 1.23 (1.09--1.39)**
  CIN2                                                 42/41, 1.24 (0.81--1.90)                                                 42/42, 1.29 (0.84--1.98)
  ⩾CIN3                                              **119/96, 1.50 (1.15--1.96)**                                             110/119, 1.20 (0.92--1.55)
  CIN treatments                                    **183/166, 1.33 (1.08--1.64)**                                             163/183, 1.15 (0.93--1.42)
  \<CIN2                                            **149/141, 1.28 (1.02--1.61)**                                             131/149, 1.14 (0.90--1.44)
  False positive for ⩾CIN2                          **325/301, 1.30 (1.12--1.52)**                                           **310/325, 1.23 (1.06--1.44)**
  False positive for ⩾CIN3                          **367/342, 1.30 (1.12--1.50)**                                           **352/367, 1.24 (1.07--1.43)**
  PPV for ⩾CIN2                                       33%/31%, 1.06 (0.88--1.28)                                               33%/33%, 0.99 (0.83--1.19)
  PPV for ⩾CIN3                                       24%/22%, 1.12 (0.88--1.41)                                               24%/24%, 0.97 (0.78--1.22)
  **45--59 years**                                           10 825/12 909                                                             8057/10 825
  ⩾ASCUS                                            **216/330, 0.78 (0.66--0.92)**                                           **230/216, 1.43 (1.19--1.72)**
  CIN2                                                 11/11, 1.19 (0.52--2.75)                                                  8/11, 0.98 (0.39--2.43)
  ⩾CIN3                                                15/24, 0.75 (0.39--1.42)                                                 20/15, 1.79 (0.92--3.50)
  CIN treatments                                       37/63, 0.70 (0.47--1.05)                                                 37/37, 1.34 (0.85--2.12)
  \<CIN2                                              106/152, 0.83 (0.65--1.06)                                             **112/106, 1.42 (1.09--1.85)**
  False positive for ⩾CIN2                          **190/295, 0.77 (0.64--0.92)**                                           **202/190, 1.43 (1.17--1.74)**
  False positive for ⩾CIN3                          **201/306, 0.78 (0.66--0.93)**                                           **210/201, 1.40 (1.16--1.70)**
  PPV for ⩾CIN2                                       12%/11%, 1.13 (0.70--1.83)                                               12%/12%, 1.01 (0.61--1.67)
  PPV for ⩾CIN3                                        7%/7%, 0.95 (0.51--1.78)                                                 9%/7%. 1.25 (0.66--2.38)

Abbreviations: ASCUS=atypical squamous cells of undetermined significance; CIN=cervical intraepithelial neoplasia; LBC=liquid-based cytology; PPV=positive predictive value; triage=in case of ASCUS at age ⩾30 years.

Bold signifies significant change comparing the two phases.

Comparison of outcomes, by age group and phase.

###### Laboratory with ThinPrep cytological technology (Odense)[a](#tA7-fn3){ref-type="fn"}

                                              Phase 2 *vs* phase 1                      Phase 3 *vs* phase 2
  -------------------------------- ------------------------------------------ ----------------------------------------
  Change in the technology                        ThinPrep LBC                        ThinPrep Imaging System
  Same technology in both phases    Manual reading, cytology triage of ASCUS   ThinPrep LBC, cytology triage of ASCUS
  **23--59 years**                               20 921/74 522                             33 614/20 921
  ⩾ASCUS                                **536/3423, 0.56 (0.51--0.61)**           **1087/536, 1.26 (1.14--1.40)**
  CIN2                                   **31/183, 0.60 (0.41--0.88)**             **106/31, 2.13 (1.43--3.17)**
  ⩾CIN3                                    163/557, 1.04 (0.88--1.24)                249/163, 0.95 (0.78--1.16)
  CIN treatments                           219/826, 0.94 (0.81--1.10)                389/219, 1.11 (0.94--1.30)
  \<CIN2                                **215/1507, 0.51 (0.44--0.59)**            **433/215, 1.25 (1.07--1.47)**
  False positive for ⩾CIN2              **342/2683, 0.45 (0.41--0.51)**            **732/342, 1.33 (1.17--1.51)**
  False positive for ⩾CIN3              **373/2866, 0.46 (0.42--0.52)**            **838/373, 1.40 (1.24--1.58)**
  PPV for ⩾CIN2                          **36%/22%, 1.67 (1.47--1.91)**              33%/36%, 0.90 (0.78--1.04)
  PPV for ⩾CIN3                          **30%/16%, 1.87 (1.61--2.17)**            **23%/30%, 0.75 (0.64--0.89)**
  **23--29 years**                                3075/14 299                                5310/3075
  ⩾ASCUS                                  208/1066, 0.91 (0.79--1.05)              **435/208, 1.21 (1.03--1.42)**
  CIN2                                      15/93, 0.75 (0.44--1.29)                **61/15, 2.35 (1.34--4.14)**
  ⩾CIN3                                    65/250, 1.21 (0.92--1.58)                 103/65, 0.92 (0.67--1.25)
  CIN treatments                           89/373, 1.11 (0.88--1.39)                 167/89, 1.09 (0.84--1.40)
  \<CIN2                                   63/372, 0.79 (0.60--1.03)                 142/63, 1.31 (0.97--1.75)
  False positive for ⩾CIN2               **128/723, 0.82 (0.68--0.99)**              271/128, 1.23 (1.00--1.51)
  False positive for ⩾CIN3               **143/816, 0.81 (0.69--0.97)**            **332/143, 1.34 (1.11--1.63)**
  PPV for ⩾CIN2                            38%/32%, 1.20 (0.99--1.45)                38%/38%, 0.98 (0.79--1.21)
  PPV for ⩾CIN3                          **31%/23%, 1.33 (1.06--1.68)**            **24%/31%, 0.76 (0.58--0.99)**
  **30--44 years**                                9342/32 819                               14 370/9342
  ⩾ASCUS                                **242/1435, 0.59 (0.52--0.68)**            **472/242, 1.27 (1.09--1.48)**
  CIN2                                      13/73, 0.63 (0.35--1.13)                  33/13, 1.65 (0.87--3.13)
  ⩾CIN3                                    80/259, 1.09 (0.85--1.39)                 132/80, 1.07 (0.81--1.41)
  CIN treatments                           102/367, 0.98 (0.78--1.21)                188/102, 1.20 (0.94--1.52)
  \<CIN2                                 **98/579, 0.59 (0.48--0.74)**               181/98, 1.20 (0.94--1.53)
  False positive for ⩾CIN2              **149/1103, 0.47 (0.40--0.56)**            **307/149, 1.34 (1.10--1.63)**
  False positive for ⩾CIN3              **162/1176, 0.48 (0.41--0.57)**            **340/162, 1.36 (1.13--1.64)**
  PPV for ⩾CIN2                          **38%/23%, 1.66 (1.38--2.00)**              35%/38%, 0.91 (0.74--1.11)
  PPV for ⩾CIN3                          **33%/18%, 1.83 (1.48--2.26)**              28%/33%, 0.85 (0.67--1.07)
  **45--59 years**                                8504/27 404                               13 934/8504
  ⩾ASCUS                                 **86/922, 0.30 (0.24--0.37)**               180/86, 1.28 (0.99--1.65)
  CIN2                                      3/17, 0.57 (0.17--1.94)                   12/3, 2.44 (0.69--8.65)
  ⩾CIN3                                     18/48, 1.21 (0.70--2.08)                **14/18, 0.47 (0.24--0.95)**
  CIN treatments                            28/86, 1.05 (0.69--1.61)                  34/28, 0.74 (0.45--1.22)
  \<CIN2                                 **54/556, 0.31 (0.24--0.41)**               110/54, 1.24 (0.90--1.72)
  False positive for ⩾CIN2               **65/857, 0.24 (0.19--0.31)**             **154/65, 1.45 (1.08--1.93)**
  False positive for ⩾CIN3               **68/874, 0.25 (0.20--0.32)**             **166/68, 1.49 (1.12--1.97)**
  PPV for ⩾CIN2                          **24%/7%, 3.46 (2.23--5.38)**             **14%/24%, 0.59 (0.35--0.99)**
  PPV for ⩾CIN3                          **21%/5%, 4.02 (2.45--6.59)**             **8%/21%, 0.37 (0.19--0.71)**

Abbreviations: ASCUS=atypical squamous cells of undetermined significance; CIN=cervical intraepithelial neoplasia; LBC=liquid-based cytology; PPV=positive predictive value; triage=in case of ASCUS at age ⩾30 years.

Bold signifies significant change comparing the two phases.

Comparison of outcomes, by age group and phase.
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